Correlation between tumor markers in pre and post treatment of pancreatic cancer patients

2021 ◽  
Vol 25 (1) ◽  
pp. 70-74
Author(s):  
N. Sivakumar ◽  
R. Arivazhagan ◽  
B. Prabasheela
Keyword(s):  
Pancreatic Cancer ◽  
Tumour Marker ◽  
Serum Marker ◽  
Carbohydrate Antigen ◽  
Tumour Markers ◽  
Post Treatment ◽  
Treatment Groups ◽  
Serum Tumour Marker ◽  
Before And After ◽  
Serum Tumour

One of the main causes of death in India is pancreas cancer. Various blood tumour indicators such as 19-9 carbohydrate antigen (CA19-9), antigen125 carbohydrate (CA125), antigen carcinoembryogenic (CEA) and alphaetoprotein (AFP) imbalance are observed in therapy for cancer. In disease predictions, thorough monitoring of the change in serum tumour markers was highly essential. The present investigation was thus conducted to examine serum marker tumour profiles before and after therapy of individuals with pancreatic cancer. The study comprised 400 individuals from both sexes suffering from pancreatic carcinogenic malignancy. In the pre and post-treatment of patients we detected serum tumour markers. In post-treatment groups, serum tumour marker levels were lower than before the individuals were treated. However, using pairs of samples t-testing at pfleg.0.05 these changes were statistically significant. Marker alterations in the serum tumour have shown risk for individuals. These alterations therefore enable the cancer individuals to predict and monitor properly.

scholarly journals Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer

1986 ◽  
Vol 53 (2) ◽  
pp. 197-202 ◽  
Author(s):  
C Haglund ◽  
P J Roberts ◽  
P Kuusela ◽  
T M Scheinin ◽  
O Mäkelä ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Tumour Marker ◽  
Serum Tumour Marker ◽  
Serum Tumour

Evaluation of a serum tumour marker‐based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma

2020 ◽  
Vol 40 (5) ◽  
pp. 1189-1200
Author(s):  
Jeongin Yoo ◽  
Min Woo Lee ◽  
Dong Ho Lee ◽  
Jeong‐Hoon Lee ◽  
Joon Koo Han
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Prediction Model ◽  
Tumour Marker ◽  
Serum Tumour Marker ◽  
Recurrence Prediction ◽  
Serum Tumour

scholarly journals Cathepsin B-Like Activity as a Serum Tumour Marker in Ovarian Carcinoma

1997 ◽  
Vol 35 (4) ◽  
Author(s):  
Maria Warwas ◽  
Halina Haczyńska ◽  
Jerzy Gerber ◽  
Marek Nowak
Keyword(s):  
Ovarian Carcinoma ◽  
Cathepsin B ◽  
Tumour Marker ◽  
Serum Tumour Marker ◽  
Serum Tumour

The Tumour Marker CA 195 in Colorectal and Pancreatic Cancer

1991 ◽  
Vol 6 (4) ◽  
pp. 241-246 ◽  
Author(s):  
P.M. Sagar ◽  
O.M. Taylor ◽  
E.H. Cooper ◽  
E.A. Benson ◽  
M.J. Mcmahon ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Pancreatic Cancer ◽  
Serum Level ◽  
Pancreatic Adenocarcinoma ◽  
Metastatic Disease ◽  
Initial Level ◽  
Tumour Marker ◽  
Tumour Markers ◽  
Normal Range ◽  
Unresectable Disease

The aim of this study was to measure the serum level of the tumour markers CA 195 and CEA in patients with either colorectal or pancreatic cancer both before and at serial intervals after operation. CA 195 and CEA were measured in 199 patients with colorectal cancer and 52 patients with pancreatic cancer. The median concentrations of CA 195 were 3.0 u/ml (interquartile range 3.0-4.5 u/ml) in patients with a Dukes’ stage A lesion, 5.8 u/ml (3.0-18.2 u/ml) in patients with a Dukes’ stage B lesion, 6.1 u/ml (3.0-24.7 u/ml) in patients with a Dukes’ stage C and 23.8 u/ml (11.1-409.0 u/ml) in patients with metastatic disease (normal range 0-7 u/ml). The median levels of CEA were 2.6 ng/ml (1.7-3.3 ng/ml) for Dukes’ stage A, 3.3 ng/ml (1.7-7.2 ng/ml) for Dukes’ stage B, 3.7 ng/ml (2.2-7.9 ng/ml) for Dukes’ stage C and 34.5 ng/ml (13.3-289.4 ng/ml) for metastatic disease. A rising level of CA 195 or CEA after operation suggested recurrence of the tumour. In none of these patients was the recurrence operable. In patients with pancreatic adenocarcinoma, the level of CA 195 was significantly higher in patients with metastatic disease but it did not discriminate between resectable and unresectable disease. The duration of survival correlated with the initial level of CA 195 (Rs = –0.66, p < 0.001).

scholarly journals Tumour markers: their use and misuse by clinicians

2003 ◽  
Vol 40 (6) ◽  
pp. 643-647 ◽  
Author(s):  
Peter J McGinley ◽  
Eric S Kilpatrick
Keyword(s):  
General Practice ◽  
Hospital Admission ◽  
Cancer Diagnosis ◽  
Specific Antigen ◽  
Tumour Marker ◽  
Tumour Markers ◽  
Appropriate Use ◽  
Laboratory Computer ◽  
Patients With Cancer ◽  
Serum Tumour

Background: Several guidelines exist on the appropriate use of serum tumour markers in the management of patients with cancer. This study audited tumour marker requesting against these guidelines in a busy teaching hospital over a 12-month period. Methods: All marker requests from 1 April 2001 to 31 March 2002 were collected using the laboratory computer. From one 24-h period, the case notes from all hospital requests [excluding prostate-specific antigen (PSA)] were examined. Results: Tumour marker workload increased by 125% from 1997-98 to 2001-02. Of 27 323 tumour marker requests, 7166 were from general practice, 2312 were requested on hospital admission before further investigation, 612/3636 of CA125 and 98/374 of CA15.3 requests were on men and 12/11585 PSA requests on women. Of 34 case notes examined, 18 had tumour markers measured before biopsy and only nine after. Of 19 patients with 'normal' markers, one had malignancy on biopsy and, of 15 with one or more raised markers, four had normal biopsies. Conclusions: Tumour marker workload is rapidly increasing. Tumour markers are frequently and inappropriately requested, either because they are on patients of the wrong sex, or because they are taken before a cancer diagnosis is reached. Results from these tests can be falsely reassuring or unduly alarming.

scholarly journals Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

2001 ◽  
Vol 84 (10) ◽  
pp. 1301-1307 ◽  
Author(s):  
M K Tuxen ◽  
G Sölétormos ◽  
P Dombernowsky
Keyword(s):  
Ovarian Cancer ◽  
Tumour Marker ◽  
Ca 125 ◽  
First Line ◽  
Serum Tumour Marker ◽  
Line Chemotherapy ◽  
Serum Tumour

Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer

2015 ◽  
Vol 68 (6) ◽  
pp. 427-433 ◽  
Author(s):  
Daniel Reitz ◽  
Armin Gerger ◽  
Julia Seidel ◽  
Peter Kornprat ◽  
Hellmut Samonigg ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Predictive Accuracy ◽  
Area Under The Curve ◽  
Carbohydrate Antigen ◽  
Tumour Markers ◽  
Cancer Specific Survival ◽  
Receiver Operating Characteristic Curves ◽  
Prognostic Prediction ◽  
Medical University ◽  
Better Than

AimsTumour markers including carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) are frequently determined at the time of diagnosis in patients with pancreatic cancer. Several studies indicate a prognostic relevance of these markers in pancreatic cancer, but space for improvement with regard to the predictive accuracy and ability is given. In this work, the main focus is on mathematical combinations of these two tumour markers in order to validate an improvement of prognostic test results in terms of sensitivity and specificity.MethodsThis retrospective study includes 393 patients with pancreatic cancer, who were treated between the years 2005 and 2012 at the Division of Oncology, Medical University of Graz, Austria. The goal of this study was to explore whether an appropriate combination of two tumour markers leads to a statistically significant improvement of the prognostic prediction.ResultsReceiver operating characteristic curves comparison analyses with the classification variable cancer-specific survival showed that the mathematical product of two tumour markers (TMproduct= (CEA×CA19-9); area under the curve (AUC)=0.727; 95% CI 0.680 to 0.770) is significantly better than CEA alone (AUC=0.644; 95% CI 0.594 to 0.691; p=0.003) but not significant compared with CA19-9 (AUC=0.710; 95% CI 0.662 to 0.754; p=0.1215). A linear combination of CEA and CA19-9 (TMlinear=(85×CEA+CA19-9); AUC=0.748; 95% CI 0.702 to 0.790) is significantly better than CEA (p<0.0001) as well as CA19-9 alone (p=0.0304).ConclusionsMathematical combinations of pretherapeutic tumour markers CEA and CA19-9 are feasible and can significantly improve the prognostic prediction in patients with pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document